David A Sallman (H Lee Moffitt Cancer Center, Tampa, FL, USA) and colleagues reported the results for the expansion cohort of the ongoing phase 1b trial of magrolimab (anti-CD47) plus azacitidine in 43 patients (median age 73 years) with untreated, intermediate to very high-risk, myelodysplastic syndrome or untreated acute myeloid leukaemia (AML). The safety profile of the drug combination, which was well tolerated, was similar to azacitidine monotherapy; treatment-related adverse events that occurred in more than 15% of patients were anaemia (37%), neutropenia (26%), and thrombocytopenia (26%). Seven (88%) of eight evaluable patients harbouring TP53 mutations—a treatment-refractory subgroup—had an objective response. Median duration response or overall survival have not been reached for patients with myelodysplastic syndrome or AML.

中文翻译：

---

2019 ASH年会。

David A Sallman（美国佛罗里达州坦帕市H Lee Moffitt癌症中心）和同事报告了正在进行的magrolimab（抗CD47）加azacitidine的1b期临床试验的扩增队列研究结果，该研究纳入了43位患者（中位年龄73岁），未经治疗，中度至极高风险，骨髓增生异常综合症或未经治疗的急性髓细胞性白血病（AML）。药物组合的安全性良好，耐受性良好，与阿扎胞苷单药治疗相似。超过15％的患者发生的与治疗相关的不良事件为贫血（37％），中性粒细胞减少症（26％）和血小板减少症（26％）。八名可评估的TP53患者中有七名（88％）突变（治疗难治性亚组）具有客观反应。骨髓增生异常综合症或AML患者的中位反应时间或总生存期尚未达到。